The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice

Chemogenetics revealed: DREADD occupancy and activation via converted clozapine

(2017) Juan L. Gomez et al.   SCIENCE

DREADDS: Use and application in behavioral neuroscience.

(2016) Kyle S. Smith et al.   BEHAVIORAL NEUROSCIENCE

The First Structure–Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs

(2015) Xin Chen et al.   ACS Chemical Neuroscience

DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility

(2015) Daniel J. Urban et al.   Annual Review of Pharmacology and Toxicology

A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior

(2015) Eyal Vardy et al.   NEURON

Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats

(2015) Nathan J Marchant et al.   NEUROPSYCHOPHARMACOLOGY

Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice

(2012) Jason M. Wiebelhaus et al.   BEHAVIOURAL PHARMACOLOGY

Disulfiram Attenuates Drug-Primed Reinstatement of Cocaine Seeking via Inhibition of Dopamine β-Hydroxylase

(2010) Jason P Schroeder et al.   NEUROPSYCHOPHARMACOLOGY

A chemical-genetic approach to study G protein regulation of β cell function in vivo

(2009) Jean-Marc Guettier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies

(2008) Joseph H. Porter et al.   PSYCHOPHARMACOLOGY